Matthews International Capital Management Boosted By $980,000 Its Netease (NTES) Stake; Galmed Pharmaceuticals LTD. – Ordinary Shares (GLMD) Sellers Decreased By 33.72% Their Shorts

June 14, 2018 - By Ina Campbell

Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD) Logo

Matthews International Capital Management Llc increased Netease Inc (NTES) stake by 1.41% reported in 2018Q1 SEC filing. Matthews International Capital Management Llc acquired 3,500 shares as Netease Inc (NTES)’s stock declined 25.93%. The Matthews International Capital Management Llc holds 251,200 shares with $70.43M value, up from 247,700 last quarter. Netease Inc now has $33.42 billion valuation. The stock decreased 0.30% or $0.76 during the last trading session, reaching $254.45. About 606,315 shares traded. NetEase, Inc. (NASDAQ:NTES) has declined 22.10% since June 14, 2017 and is downtrending. It has underperformed by 34.67% the S&P500. Some Historical NTES News: ; 13/03/2018 – NETEASE CLOUD MUSIC – TO SUBLICENSE PREMIER MUSIC COPYRIGHTS OWNED BY EE-MEDIA, AVEX, FORWARD MUSIC, HIM INTERNATIONAL MUSIC, AND OTHERS TO ALIMUSIC; 26/03/2018 – BEIJING — Chinese internet technology services provider NetEase will try to maintain double-digit growth by making its online retail arm as large as its core mobile games business, according to CEO and founder William Ding Lei; 15/05/2018 – Peak6 Investments Adds Netease, Exits Apple, Cuts Facebook: 13F; 08/03/2018 – MMORPG Crusaders of Light Launches on Steam with New Server and Major Content Update; 16/05/2018 – MEDIA-New international Beijing airport to open October next year – China Daily; 15/03/2018 – Anna Nicolaou: scoop: the top indie record labels are going to stream in china. Merlin struck a deal with 5 services, owned by; 14/05/2018 – Comgest Exits Criteo, Cuts Netease, Buys More Cognizant: 13F; 25/04/2018 – NETEASE INC NTES.O : CLSA RAISES TO OUTPERFORM FROM UNDERPERFORM; 04/05/2018 – NetEase’s CEO Sees a Third of His Fortune Vanish in Six Months; 17/05/2018 – ADRs End Mostly Lower; NetEase Trades Actively

Galmed Pharmaceuticals LTD. – Ordinary Shares (NASDAQ:GLMD) had a decrease of 33.72% in short interest. GLMD’s SI was 22,800 shares in June as released by FINRA. Its down 33.72% from 34,400 shares previously. With 40,400 avg volume, 1 days are for Galmed Pharmaceuticals LTD. – Ordinary Shares (NASDAQ:GLMD)’s short sellers to cover GLMD’s short positions. The SI to Galmed Pharmaceuticals LTD. – Ordinary Shares’s float is 0.31%. The stock decreased 6.46% or $1.16 during the last trading session, reaching $16.8. About 994,289 shares traded or 170.09% up from the average. Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD) has risen 23.87% since June 14, 2017 and is uptrending. It has outperformed by 11.30% the S&P500. Some Historical GLMD News: ; 03/04/2018 – GALMED PHARMACEUTICALS – ENTERED INTO SECURITIES PURCHASE AGREEMENT WITH BIOTECHNOLOGY VALUE FUND, L.P. AND CERTAIN OF ITS AFFILIATES; 19/03/2018 – Galmed Pharma at Investor Day Hosted By H.C. Wainwright Today; 07/05/2018 – Galmed Pharma Access Event Set By LifeSci Advisors for May. 14; 16/04/2018 – Galmed Pharmaceuticals to Host Post-EASL Key Opinion Leader Call on the Scientific Rationale and Clinical Development of Aramchol™ for NASH; 27/03/2018 – Galmed Pharmaceuticals to Present New Scientific Data on the Mechanism by Which Aramchol Exerts its Effect on Fibrosis at EASL; 08/05/2018 – Galmed Pharma Access Event Set By LifeSci Advisors for May. 15; 09/05/2018 – GALMED PHARMACEUTICALS LTD – REAFFIRMING SCHEDULE OF RELEASE OF ARREST STUDY TOP LINE RESULTS; 27/04/2018 – Galmed Pharma Access Event Set By LifeSci Advisors for Apr. 30; 16/04/2018 – Galmed Pharmaceuticals to Host Post-EASL Key Opinion Leader Call on the Scientific Rationale and Clinical Development of Aramch; 13/03/2018 Galmed Pharmaceuticals 4Q Loss/Shr 27c

Galmed Pharmaceuticals Ltd., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of liver diseases. The company has market cap of $259.31 million. The firm is developing Aramchol, an oral therapy, which is in ARREST study, a Phase IIb clinical study for the treatment of patients with overweight or obesity, and who are pre-diabetic or type-II-diabetic with non-alcoholic steato-hepatitis. It currently has negative earnings. It is also evaluating Aramchol through ARRIVE Study, a proof-of-concept Phase IIa clinical trial, with HIV-associated non-alcoholic fatty liver disease and lipodystrophy.

Among 5 analysts covering Galmed Pharmaceuticals Ltd (NASDAQ:GLMD), 5 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Galmed Pharmaceuticals Ltd had 10 analyst reports since August 14, 2015 according to SRatingsIntel. The stock has “Buy” rating by H.C. Wainwright on Tuesday, August 8. The firm has “Buy” rating by Maxim Group given on Monday, July 31. The firm has “Buy” rating by H.C. Wainwright given on Monday, March 28. The firm has “Buy” rating by Roth Capital given on Thursday, August 13. The stock of Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD) has “Buy” rating given on Wednesday, June 13 by Maxim Group. Maxim Group upgraded Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD) on Thursday, March 15 to “Buy” rating. As per Wednesday, February 14, the company rating was downgraded by Maxim Group.

More notable recent Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD) news were published by: Seekingalpha.com which released: “Galmed Pharmaceuticals: Is The Pop Justified?” on June 14, 2018, also Streetinsider.com with their article: “Pre-Open Movers 06/12: (GLMD) (RH) (PLAY) Higher; (IDRA) (JCAP) (IMMU) Lower (more…)” published on June 12, 2018, Fool.com published: “Are These Red-Hot NASH Stocks Still a Buy?” on June 14, 2018. More interesting news about Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD) were released by: Nasdaq.com and their article: “Mid-Afternoon Market Update: Enzo Biochem Falls After Q3 Results; Galmed Pharmaceuticals Shares Surge” published on June 12, 2018 as well as Streetinsider.com‘s news article titled: “Galmed Pharma (GLMD) Plans Conference Call to Discuss Top-Line, 52-Week Results from Global Phase 2b ARREST …” with publication date: June 11, 2018.

More important recent NetEase, Inc. (NASDAQ:NTES) news were published by: Seekingalpha.com which released: “NetEase: Compelling Buying Opportunity” on June 04, 2018, also Seekingalpha.com published article titled: “NetEase -9.1% after miss, analyst caution on costs”, Seekingalpha.com published: “Best And Worst Performing Nasdaq 100 Stocks Of 2018” on May 25, 2018. More interesting news about NetEase, Inc. (NASDAQ:NTES) was released by: Seekingalpha.com and their article: “NetEase unveils 20 new games in pipeline” with publication date: May 22, 2018.

Among 20 analysts covering NetEase (NASDAQ:NTES), 13 have Buy rating, 4 Sell and 3 Hold. Therefore 65% are positive. NetEase had 48 analyst reports since August 12, 2015 according to SRatingsIntel. The stock has “Overweight” rating by Morgan Stanley on Thursday, November 10. Jefferies maintained NetEase, Inc. (NASDAQ:NTES) rating on Monday, December 18. Jefferies has “Hold” rating and $345.0 target. On Thursday, November 16 the stock rating was maintained by Jefferies with “Hold”. The company was downgraded on Friday, October 16 by Standpoint Research. As per Wednesday, August 26, the company rating was upgraded by Standpoint Research. The firm earned “Buy” rating on Thursday, May 12 by Nomura. The firm has “Sell” rating by CLSA given on Thursday, November 16. The firm earned “Sell” rating on Wednesday, June 7 by Standpoint Research. Macquarie Research maintained it with “Outperform” rating and $280 target in Wednesday, September 28 report. The firm earned “Hold” rating on Tuesday, October 3 by Jefferies.

NetEase, Inc. (NASDAQ:NTES) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.




Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: